Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 11/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2313853 | 1.00 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL2312734 | 1.00 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL1748113 | 0.98 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL6031677 | 0.98 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL1748115 | 0.98 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL1748114 | 0.98 | HDAC6 (0.53) | HDAC6DGAT1ROCK1HDAC3HDAC1 | |
| SCHEMBL2306717 | 0.92 | DGAT1 (0.48) | HDAC6DGAT1MAPTRAB9A | |
| SCHEMBL2306323 | 0.92 | DGAT1 (0.48) | HDAC6DGAT1MAPTRAB9A | |
| SCHEMBL2312889 | 0.92 | DGAT1 (0.48) | HDAC6DGAT1MAPTRAB9A | |
| SCHEMBL2311869 | 0.90 | HDAC6 (0.46) | HDAC6DGAT1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | claimed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | claimed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | claimed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | claimed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
| EP-1633722-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | claimed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | claimed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | HDAC6 522/4885DGAT1 34/4885ROCK1 4141/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | HDAC6 522/4885DGAT1 34/4885ROCK1 4141/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | HDAC6 522/4885DGAT1 34/4885ROCK1 4141/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | HDAC6 522/4885DGAT1 34/4885ROCK1 4141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.